Teeple, A, and E Muser. 2018. “Cost Per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients With Moderate to Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 2 (December):S80. https://doi.org/10.25251/skin.2.supp.81.